SDGR - Absci hits new 52-week high as AI drug discovery rallies
2023-12-26 13:19:21 ET
More on AbCellera Biologics, Absci, etc.
- Exscientia Looks Promising In AI-Driven Drug Development
- AbCellera: Difficult 2023 Suggests Business Model Should Pivot In 2024
- Buy AbCellera Biologics's Revolutionizing AI-Powered Drug Development Platform
- KeyBanc sees opportunity in tech-enabled drug discovery stocks
- AstraZeneca in pact with Absci to develop cancer drug based on AI
For further details see:
Absci hits new 52-week high as AI drug discovery rallies